CytomX Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Okay. Great. Thanks for joining us, everyone. I'm Terence Flynn, one of the biotech analysts here at Goldman. And we're very pleased to have CytomX. Joining us from the company is Sean McCarthy, CEO. Sean, I'm going to turn it over to you for some opening remarks before we launch into questions.
Great. Thanks, Terence. Pleasure to be here. It's been a great couple of days. So we set out several years ago to reimagine therapeutic antibodies for the treatment of various diseases actually in the early incarnation of the company. Over the last 4 or 5 years, we focused on oncology, which is an obvious application for what we do. And this reimagination process is really focused on a very unique platform that we call Probodies. Probodies are therapeutic antibodies that are designed to be localized into disease tissue, so into cancer tissue and really to fundamentally alter the distribution of an active antibody in a patient.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |